Haemonetics [HAE] vs Bruker [BRKR] Detailed Stock Comparison
Haemonetics
NYSE
Loading...
Bruker
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Haemonetics wins in 14 metrics, Bruker wins in 5 metrics, with 0 ties. Haemonetics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Haemonetics | Bruker | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 16.73 | 59.29 | Haemonetics |
| Price-to-Book Ratio | 2.99 | 2.59 | Bruker |
| Debt-to-Equity Ratio | 138.87 | 132.75 | Bruker |
| PEG Ratio | -2.74 | 11.38 | Haemonetics |
| EV/EBITDA | 9.57 | 12.77 | Haemonetics |
| Profit Margin (TTM) | 12.14% | 2.31% | Haemonetics |
| Operating Margin (TTM) | 20.21% | 3.61% | Haemonetics |
| EBITDA Margin (TTM) | 20.21% | 3.61% | Haemonetics |
| Return on Equity | 18.27% | 4.07% | Haemonetics |
| Return on Assets (TTM) | 6.52% | 3.55% | Haemonetics |
| Free Cash Flow (TTM) | $142.45M | $136.00M | Haemonetics |
| 1-Year Return | -25.75% | -51.84% | Haemonetics |
| Price-to-Sales Ratio (TTM) | 1.96 | 1.36 | Bruker |
| Enterprise Value | $3.54B | $7.12B | Bruker |
| EV/Revenue Ratio | 2.63 | 2.07 | Bruker |
| Gross Profit Margin (TTM) | 59.82% | 44.88% | Haemonetics |
| Revenue per Share (TTM) | $27 | $23 | Haemonetics |
| Earnings per Share (Diluted) | $3.27 | $0.52 | Haemonetics |
| Beta (Stock Volatility) | 0.39 | 1.21 | Haemonetics |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Haemonetics vs Bruker Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Haemonetics | 0.55% | -0.29% | -28.55% | -22.76% | -19.03% | -30.64% |
| Bruker | 3.49% | -9.27% | -3.87% | -18.20% | -34.22% | -47.58% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Haemonetics | -25.75% | -29.26% | -38.73% | 52.41% | 97.96% | 139.35% |
| Bruker | -51.84% | -47.11% | -23.69% | 70.33% | 128.88% | 585.11% |
Performance & Financial Health Analysis: Haemonetics vs Bruker
| Metric | HAE | BRKR |
|---|---|---|
| Market Information | ||
| Market Cap | $2.62B | $4.68B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 722,467 | 5,790,090 |
| 90 Day Avg. Volume | 1,063,762 | 4,236,277 |
| Last Close | $54.38 | $30.83 |
| 52 Week Range | $50.68 - $94.99 | $28.53 - $72.94 |
| % from 52W High | -42.75% | -57.73% |
| All-Time High | $142.11 (Feb 08, 2021) | $94.86 (Mar 18, 2024) |
| % from All-Time High | -61.73% | -67.50% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.04% | 0.00% |
| Quarterly Earnings Growth | -0.11% | 0.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.12% | 0.02% |
| Operating Margin (TTM) | 0.20% | 0.04% |
| Return on Equity (TTM) | 0.18% | 0.04% |
| Debt to Equity (MRQ) | 138.87 | 132.75 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $18.32 | $11.89 |
| Cash per Share (MRQ) | $6.10 | $0.65 |
| Operating Cash Flow (TTM) | $226.54M | $165.90M |
| Levered Free Cash Flow (TTM) | $233.10M | $223.20M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Haemonetics vs Bruker
| Metric | HAE | BRKR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 16.73 | 59.29 |
| Forward P/E | 10.24 | 11.38 |
| PEG Ratio | -2.74 | 11.38 |
| Price to Sales (TTM) | 1.96 | 1.36 |
| Price to Book (MRQ) | 2.99 | 2.59 |
| Market Capitalization | ||
| Market Capitalization | $2.62B | $4.68B |
| Enterprise Value | $3.54B | $7.12B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.63 | 2.07 |
| Enterprise to EBITDA | 9.57 | 12.77 |
| Risk & Other Metrics | ||
| Beta | 0.39 | 1.21 |
| Book Value per Share (MRQ) | $18.32 | $11.89 |
Financial Statements Comparison: Haemonetics vs Bruker
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HAE | BRKR |
|---|---|---|
| Revenue/Sales | $321.39M | $801.40M |
| Cost of Goods Sold | $129.15M | $410.20M |
| Gross Profit | $192.24M | $391.20M |
| Research & Development | $16.26M | $97.10M |
| Operating Income (EBIT) | $53.87M | $65.70M |
| EBITDA | $82.63M | $118.60M |
| Pre-Tax Income | $45.17M | $25.10M |
| Income Tax | $11.14M | $8.70M |
| Net Income (Profit) | $34.03M | $16.80M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HAE | BRKR |
|---|---|---|
| Cash & Equivalents | $306.76M | $184.20M |
| Total Current Assets | $934.98M | $2.11B |
| Total Current Liabilities | $578.11M | $1.34B |
| Long-Term Debt | $921.23M | $2.08B |
| Total Shareholders Equity | $820.84M | $1.85B |
| Retained Earnings | $352.17M | $2.42B |
| Property, Plant & Equipment | $395.15M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HAE | BRKR |
|---|---|---|
| Operating Cash Flow | $98.50M | $55.70M |
| Capital Expenditures | $2.45M | $-26.00M |
| Free Cash Flow | $100.91M | $39.00M |
| Debt Repayment | $-1.56M | $-175.60M |
| Common Stock Repurchase | $-150.00M | $-10.00M |
Short Interest & Institutional Ownership Analysis
| Metric | HAE | BRKR |
|---|---|---|
| Shares Short | 4.37M | 6.65M |
| Short Ratio | 4.26 | 1.75 |
| Short % of Float | 0.12% | 0.09% |
| Average Daily Volume (10 Day) | 722,467 | 5,790,090 |
| Average Daily Volume (90 Day) | 1,063,762 | 4,236,277 |
| Shares Outstanding | 48.22M | 151.68M |
| Float Shares | 47.60M | 103.14M |
| % Held by Insiders | 0.01% | 0.32% |
| % Held by Institutions | 1.16% | 0.84% |
Dividend Analysis & Yield Comparison: Haemonetics vs Bruker
| Metric | HAE | BRKR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |